Perspectives on Medicare’s Proposed iDose TR Coverage Policy

Six glaucoma specialists discuss Medicare's proposed local coverage determinations (LCDs) for iDose TR and how they could affect patient care.

By: Steven R. Sarkisian, Jr., MD, Inder Paul Singh, MD, Savak “Sev” Teymoorian, MD, MBA, Manjool Shah, MD, Christine Funke, MD, Philip S. Garza, MD, MSc

Glaucoma Physician September 1, 2026 Page(s): 21-23

Inder Paul Singh, MD

Specialties: Glaucoma

Bio: Inder Paul Singh, MD, is an ophthalmology author whose work in the provided source focuses on glaucoma care and selective laser trabeculoplasty (SLT). He coauthored a Glaucoma Physician article discussing SLT as an intraocular pressure-lowering therapy across patient populations, including eyes after laser peripheral iridotomy and patients with primary angle-closure or primary open-angle glaucoma.

Perspectives on Medicare’s Proposed iDose TR Coverage Policy

Recommendations